Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
1999-2-11
|
| pubmed:abstractText |
Medical prescription of hematopoietic growth factors (HGF) was analysed in 19 anticancer french centers during 2 months. About 4% of anticancer chemotherapeutic cycles prescribed during this period were supported by HGF prescription. The mean duration of treatment was 8 days. Among the 755 collected prescriptions, two tumor localizations represented about 50% of the prescriptions: malignant non Hodgkin lymphomas and breast cancer. The other main localizations concerned adult or pediatric soft tissue sarcomas (18%), testicular cancer (7%) and gynecologic tumors (6%). The prescription for primary prophylaxis for febrile neutropenia remains the main use of HGF (44%). The respect of the guidelines established by the F|d|ration nationale des centres de lutte contre le cancer was analyzed. Overall, 66% of the prescriptions were in adequation with these guidelines. Whereas the consommation of HGF decreased in the 19 considered institutions, it did not reach a plateau and could decrease in institutions which are awaked to the international and national recommendations.
|
| pubmed:language |
fre
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0007-4551
|
| pubmed:author |
pubmed-author:BénardII,
pubmed-author:BertrandCC,
pubmed-author:BrièreMM,
pubmed-author:BrunellePP,
pubmed-author:CanalPP,
pubmed-author:CarpentierYY,
pubmed-author:ChevrierRR,
pubmed-author:CourbardMM,
pubmed-author:DolyMM,
pubmed-author:DubanMM,
pubmed-author:GautiéLL,
pubmed-author:GermanOO,
pubmed-author:GosselinPP,
pubmed-author:LatourJ FJF,
pubmed-author:MenguyAA,
pubmed-author:PinguetFF,
pubmed-author:PommierMM,
pubmed-author:PrebayDD,
pubmed-author:ViauPP,
pubmed-author:WateletMM,
pubmed-author:de La JarriageP LPL
|
| pubmed:issnType |
Print
|
| pubmed:volume |
85
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1043-8
|
| pubmed:dateRevised |
2009-11-11
|
| pubmed:meshHeading |
pubmed-meshheading:9917555-Adult,
pubmed-meshheading:9917555-Cancer Care Facilities,
pubmed-meshheading:9917555-Drug Costs,
pubmed-meshheading:9917555-Drug Prescriptions,
pubmed-meshheading:9917555-Drug Utilization,
pubmed-meshheading:9917555-Female,
pubmed-meshheading:9917555-France,
pubmed-meshheading:9917555-Hematopoietic Cell Growth Factors,
pubmed-meshheading:9917555-Humans,
pubmed-meshheading:9917555-Male,
pubmed-meshheading:9917555-Neoplasms,
pubmed-meshheading:9917555-Patient Selection,
pubmed-meshheading:9917555-Practice Guidelines as Topic,
pubmed-meshheading:9917555-Prospective Studies,
pubmed-meshheading:9917555-Time Factors
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
[Analysis of hematopoietic growth factor prescriptions in 19 french cancer centers].
|
| pubmed:affiliation |
Institut Claudius-Regaud, 20-24, rue du Pont-Saint-Pierre, 31052 Toulouse Cedex.
|
| pubmed:publicationType |
Journal Article,
English Abstract
|